The Food and Drug Administration (FDA) has officially pushed back the timeline for its safety review of mifepristone, a medication commonly used for medical abortions. According to a court filing submitted on Wednesday, the agency does not expect to conclude its assessment until March.

In addition to the timeline update, the FDA stated that it will refrain from imposing any new regulatory restrictions on the drug while the review process is ongoing. This decision maintains the current status quo for access to the medication, which has been a focal point of ongoing legal and political debates regarding reproductive healthcare access in the United States.

The announcement comes amid heightened scrutiny of the drug's availability. While the FDA maintains its regulatory oversight, the delay in the review process has become a point of contention for various advocacy groups. Anti-abortion activists have expressed frustration with the pace of the agency's actions, suggesting that the current timeline is insufficient. Conversely, reproductive rights advocates have closely monitored the situation, concerned that any potential new restrictions could significantly impact patient access to abortion services. The FDA has not provided specific details on what the safety review entails or what potential changes, if any, might be considered once the process concludes in the spring.